Fulton Breakefield Broenniman LLC lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 0.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 297,273 shares of the biopharmaceutical company’s stock after selling 2,186 shares during the quarter. Pfizer makes up about 2.0% of Fulton Breakefield Broenniman LLC’s portfolio, making the stock its 14th biggest position. Fulton Breakefield Broenniman LLC’s holdings in Pfizer were worth $13,101,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors also recently made changes to their positions in PFE. Schaper Benz & Wise Investment Counsel Inc. WI raised its stake in Pfizer by 0.5% in the 3rd quarter. Schaper Benz & Wise Investment Counsel Inc. WI now owns 228,630 shares of the biopharmaceutical company’s stock worth $10,076,000 after acquiring an additional 1,170 shares during the last quarter. Clean Yield Group raised its stake in Pfizer by 1.9% in the 3rd quarter. Clean Yield Group now owns 64,375 shares of the biopharmaceutical company’s stock worth $2,837,000 after acquiring an additional 1,170 shares during the last quarter. Adams Asset Advisors LLC raised its stake in Pfizer by 0.8% in the 3rd quarter. Adams Asset Advisors LLC now owns 157,717 shares of the biopharmaceutical company’s stock worth $6,951,000 after acquiring an additional 1,182 shares during the last quarter. Exeter Financial LLC raised its stake in Pfizer by 3.9% in the 2nd quarter. Exeter Financial LLC now owns 31,817 shares of the biopharmaceutical company’s stock worth $1,154,000 after acquiring an additional 1,195 shares during the last quarter. Finally, Smart Portfolios LLC raised its stake in Pfizer by 43.9% in the 2nd quarter. Smart Portfolios LLC now owns 3,935 shares of the biopharmaceutical company’s stock worth $143,000 after acquiring an additional 1,200 shares during the last quarter. 69.26% of the stock is currently owned by institutional investors and hedge funds.
In other Pfizer news, major shareholder Pfizer Inc bought 55,556 shares of the company’s stock in a transaction dated Monday, October 15th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $1,000,008.00. Following the transaction, the insider now directly owns 21,976,484 shares of the company’s stock, valued at $395,576,712. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. 0.06% of the stock is owned by company insiders.
NYSE PFE opened at $43.43 on Wednesday. The stock has a market cap of $255.97 billion, a price-to-earnings ratio of 16.39, a P/E/G ratio of 2.10 and a beta of 0.87. Pfizer Inc. has a fifty-two week low of $33.20 and a fifty-two week high of $46.47. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.47.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, October 30th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.75 by $0.03. The business had revenue of $13.30 billion during the quarter, compared to analyst estimates of $13.53 billion. Pfizer had a return on equity of 25.26% and a net margin of 44.63%. The company’s revenue was up 1.0% on a year-over-year basis. During the same quarter last year, the business posted $0.67 EPS. Analysts forecast that Pfizer Inc. will post 3 EPS for the current year.
Pfizer announced that its board has approved a share buyback plan on Friday, December 14th that allows the company to buyback $10.00 billion in outstanding shares. This buyback authorization allows the biopharmaceutical company to purchase up to 3.8% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s leadership believes its shares are undervalued.
The firm also recently announced a quarterly dividend, which will be paid on Friday, March 1st. Stockholders of record on Friday, February 1st will be given a dividend of $0.36 per share. The ex-dividend date is Thursday, January 31st. This is a boost from Pfizer’s previous quarterly dividend of $0.34. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.32%. Pfizer’s dividend payout ratio (DPR) is 51.32%.
A number of equities analysts recently issued reports on PFE shares. Cantor Fitzgerald set a $45.00 target price on Pfizer and gave the stock a “buy” rating in a research note on Thursday, October 4th. Morgan Stanley set a $45.00 target price on Pfizer and gave the stock a “buy” rating in a research note on Thursday, September 13th. Goldman Sachs Group restated a “neutral” rating and issued a $45.00 target price on shares of Pfizer in a research note on Tuesday, October 30th. Credit Suisse Group set a $45.00 target price on Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, January 1st. Finally, Independent Research set a $48.00 target price on Pfizer and gave the stock a “neutral” rating in a research note on Thursday, October 4th. Two research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and eight have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $43.41.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Featured Article: Balance Sheet
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.